JP2020512388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512388A5 JP2020512388A5 JP2019554037A JP2019554037A JP2020512388A5 JP 2020512388 A5 JP2020512388 A5 JP 2020512388A5 JP 2019554037 A JP2019554037 A JP 2019554037A JP 2019554037 A JP2019554037 A JP 2019554037A JP 2020512388 A5 JP2020512388 A5 JP 2020512388A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- recombinant antibody
- sequence described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 566
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 86
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 86
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 74
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 claims description 18
- 238000010494 dissociation reaction Methods 0.000 claims description 18
- 230000005593 dissociations Effects 0.000 claims description 18
- 102000046645 human LIF Human genes 0.000 claims description 18
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 16
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 16
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 16
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 10
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 claims description 8
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 6
- 238000000034 method Methods 0.000 description 132
- 206010028980 Neoplasm Diseases 0.000 description 43
- 201000011510 cancer Diseases 0.000 description 43
- 235000001014 amino acid Nutrition 0.000 description 18
- 206010009944 Colon cancer Diseases 0.000 description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 13
- 206010033128 Ovarian cancer Diseases 0.000 description 13
- 206010061535 Ovarian neoplasm Diseases 0.000 description 13
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 13
- 206010060862 Prostate cancer Diseases 0.000 description 13
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 13
- 208000029742 colonic neoplasm Diseases 0.000 description 13
- 208000005017 glioblastoma Diseases 0.000 description 13
- 201000005202 lung cancer Diseases 0.000 description 13
- 208000020816 lung neoplasm Diseases 0.000 description 13
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 13
- 201000002528 pancreatic cancer Diseases 0.000 description 13
- 208000008443 pancreatic carcinoma Diseases 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 6
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 4
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 4
- 239000012830 cancer therapeutic Substances 0.000 description 4
- -1 carrier Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 3
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 3
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 3
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 3
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 3
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 3
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 3
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022105552A JP7459173B2 (ja) | 2016-12-19 | 2022-06-30 | Ｌｉｆに対する抗体及びその使用 |
| JP2024044049A JP2024075682A (ja) | 2016-12-19 | 2024-03-19 | Ｌｉｆに対する抗体及びその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382617.5 | 2016-12-19 | ||
| EP16382617 | 2016-12-19 | ||
| US201762467017P | 2017-03-03 | 2017-03-03 | |
| US62/467,017 | 2017-03-03 | ||
| EP17382683.5 | 2017-10-13 | ||
| EP17382683 | 2017-10-13 | ||
| PCT/IB2017/001677 WO2018115960A1 (en) | 2016-12-19 | 2017-12-18 | Antibodies against lif and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022105552A Division JP7459173B2 (ja) | 2016-12-19 | 2022-06-30 | Ｌｉｆに対する抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512388A JP2020512388A (ja) | 2020-04-23 |
| JP2020512388A5 true JP2020512388A5 (enExample) | 2021-05-13 |
| JP7100056B2 JP7100056B2 (ja) | 2022-07-12 |
Family
ID=67138942
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554037A Active JP7100056B2 (ja) | 2016-12-19 | 2017-12-18 | Ｌｉｆに対する抗体及びその使用 |
| JP2022105552A Active JP7459173B2 (ja) | 2016-12-19 | 2022-06-30 | Ｌｉｆに対する抗体及びその使用 |
| JP2024044049A Pending JP2024075682A (ja) | 2016-12-19 | 2024-03-19 | Ｌｉｆに対する抗体及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022105552A Active JP7459173B2 (ja) | 2016-12-19 | 2022-06-30 | Ｌｉｆに対する抗体及びその使用 |
| JP2024044049A Pending JP2024075682A (ja) | 2016-12-19 | 2024-03-19 | Ｌｉｆに対する抗体及びその使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11390670B2 (enExample) |
| EP (2) | EP3555132B1 (enExample) |
| JP (3) | JP7100056B2 (enExample) |
| KR (3) | KR102784394B1 (enExample) |
| CN (2) | CN118652335A (enExample) |
| AU (1) | AU2017381585B2 (enExample) |
| BR (1) | BR112019012691A2 (enExample) |
| CA (1) | CA3047528A1 (enExample) |
| CL (2) | CL2019001717A1 (enExample) |
| DK (1) | DK3555132T3 (enExample) |
| ES (1) | ES2971126T3 (enExample) |
| FI (1) | FI3555132T3 (enExample) |
| HR (1) | HRP20240195T8 (enExample) |
| HU (1) | HUE065241T2 (enExample) |
| IL (2) | IL267450B (enExample) |
| LT (1) | LT3555132T (enExample) |
| MX (2) | MX2019007376A (enExample) |
| NZ (1) | NZ755004A (enExample) |
| PL (1) | PL3555132T3 (enExample) |
| RS (1) | RS65187B1 (enExample) |
| SA (1) | SA519402119B1 (enExample) |
| SI (1) | SI3555132T1 (enExample) |
| SM (1) | SMT202400065T1 (enExample) |
| ZA (1) | ZA201904533B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019007376A (es) * | 2016-12-19 | 2020-02-07 | Mosaic Biomedicals S L U | Anticuerpos contra el lif y usos de los mismos. |
| JP7423598B2 (ja) * | 2018-04-12 | 2024-01-29 | メドイミューン・リミテッド | がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ |
| WO2021110873A1 (en) * | 2019-12-04 | 2021-06-10 | Medimmune Limited | Antibodies against lif and uses thereof |
| TWI841810B (zh) | 2020-01-24 | 2024-05-11 | 日商西斯美股份有限公司 | 提升抗體對抗原之親和性的方法及其用途 |
| AU2021414160B2 (en) | 2020-12-31 | 2025-08-07 | Nona Biosciences (Suzhou) Co., Ltd. | Human lifr antigen binding protein, preparation method therefor, and application thereof |
| CN117396510A (zh) * | 2021-05-14 | 2024-01-12 | 基因泰克公司 | Trem2的激动剂 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| AU4231393A (en) | 1992-05-08 | 1993-12-13 | Genentech Inc. | Antibodies to leukemia inhibitory factor |
| WO1993023665A1 (en) | 1992-05-15 | 1993-11-25 | Re/Map Incorporated | Electromagnetic shielding for a liquid conditioning device |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| ATE233570T1 (de) | 1995-04-24 | 2003-03-15 | Genentech Inc | Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| CA2480052A1 (en) | 2002-04-01 | 2003-10-16 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1612558A1 (en) | 2004-06-30 | 2006-01-04 | Academisch Ziekenhuis Leiden | Method for detecting gluten |
| EA201100642A1 (ru) | 2005-04-25 | 2011-12-30 | Пфайзер Инк. | Антитела к миостатину |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| US20110135645A1 (en) | 2006-10-04 | 2011-06-09 | The Scripps Research Institute | Human antibodies neutralizing human metapneumovirus |
| CN101440128A (zh) | 2007-11-21 | 2009-05-27 | 中国人民解放军第二军医大学 | 人脑胶质瘤中差异表达的蛋白及其用途 |
| EP2356270B1 (en) * | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| ES2363358B1 (es) | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| US8221753B2 (en) * | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| US20120301463A1 (en) | 2009-09-30 | 2012-11-29 | President And Fellows Of Harvard College | Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products |
| WO2011057144A2 (en) | 2009-11-06 | 2011-05-12 | La Jolla Institute For Allergy And Immunology | Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses |
| CN102167742B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗her2单克隆抗体、其制备方法及用途 |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| KR102420934B1 (ko) | 2013-03-11 | 2022-07-15 | 젠자임 코포레이션 | 과글리코실화된 결합 폴리펩티드 |
| US20140314741A1 (en) | 2013-04-18 | 2014-10-23 | Developmen Center For Biotechnology | Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases |
| EP3037434B1 (en) | 2013-08-20 | 2018-07-18 | Japan Science and Technology Agency | Human antibody kappa type light chain complex-containing composition and method for producing same |
| US20150056195A1 (en) | 2013-08-23 | 2015-02-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy |
| EP3049110A2 (en) | 2013-09-23 | 2016-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for targeting tumor microenvironment and for preventing metastasis |
| AU2014331923B2 (en) | 2013-10-09 | 2020-02-06 | Research Development Foundation | Monoclonal Olfml-3 antibodies and uses thereof |
| TWI486172B (zh) | 2013-11-08 | 2015-06-01 | Univ Chang Gung | 鼻咽癌治療的醫藥 |
| AU2015204674B2 (en) | 2014-01-10 | 2020-09-03 | Anaptysbio, Inc. | Antibodies directed against interleukin-33 (IL-33) |
| EP4640239A2 (en) | 2014-03-19 | 2025-10-29 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| CA2958685A1 (en) | 2014-09-10 | 2016-03-17 | The Regents Of The University Of California | Targeting k-ras-mediated signaling pathways and malignancy by anti-hlif antibodies |
| EP3173483A1 (en) | 2015-11-27 | 2017-05-31 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Agents for the treatment of diseases associated with undesired cell proliferation |
| MX2019007376A (es) * | 2016-12-19 | 2020-02-07 | Mosaic Biomedicals S L U | Anticuerpos contra el lif y usos de los mismos. |
| US10583191B2 (en) * | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
| JP7423598B2 (ja) * | 2018-04-12 | 2024-01-29 | メドイミューン・リミテッド | がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ |
| JP7520727B2 (ja) * | 2018-06-18 | 2024-07-23 | メドイミューン・リミテッド | 癌を有する個人における抗ｌｉｆ抗体治療に対する反応を向上させるための方法 |
-
2017
- 2017-12-18 MX MX2019007376A patent/MX2019007376A/es unknown
- 2017-12-18 AU AU2017381585A patent/AU2017381585B2/en active Active
- 2017-12-18 ES ES17840489T patent/ES2971126T3/es active Active
- 2017-12-18 IL IL267450A patent/IL267450B/en unknown
- 2017-12-18 PL PL17840489.3T patent/PL3555132T3/pl unknown
- 2017-12-18 US US16/470,896 patent/US11390670B2/en active Active
- 2017-12-18 NZ NZ755004A patent/NZ755004A/en unknown
- 2017-12-18 LT LTEPPCT/IB2017/001677T patent/LT3555132T/lt unknown
- 2017-12-18 BR BR112019012691-0A patent/BR112019012691A2/pt unknown
- 2017-12-18 CN CN202410972902.5A patent/CN118652335A/zh active Pending
- 2017-12-18 HR HRP20240195TT patent/HRP20240195T8/hr unknown
- 2017-12-18 FI FIEP17840489.3T patent/FI3555132T3/fi active
- 2017-12-18 KR KR1020247033540A patent/KR102784394B1/ko active Active
- 2017-12-18 HU HUE17840489A patent/HUE065241T2/hu unknown
- 2017-12-18 EP EP17840489.3A patent/EP3555132B1/en active Active
- 2017-12-18 JP JP2019554037A patent/JP7100056B2/ja active Active
- 2017-12-18 SM SM20240065T patent/SMT202400065T1/it unknown
- 2017-12-18 IL IL294088A patent/IL294088B2/en unknown
- 2017-12-18 CA CA3047528A patent/CA3047528A1/en active Pending
- 2017-12-18 SI SI201731487T patent/SI3555132T1/sl unknown
- 2017-12-18 RS RS20240203A patent/RS65187B1/sr unknown
- 2017-12-18 KR KR1020237027761A patent/KR102716931B1/ko active Active
- 2017-12-18 EP EP23209620.6A patent/EP4321219A3/en active Pending
- 2017-12-18 CN CN201780086859.0A patent/CN111868086B/zh active Active
- 2017-12-18 KR KR1020197021098A patent/KR102599557B1/ko active Active
- 2017-12-18 DK DK17840489.3T patent/DK3555132T3/da active
-
2019
- 2019-06-17 SA SA519402119A patent/SA519402119B1/ar unknown
- 2019-06-19 CL CL2019001717A patent/CL2019001717A1/es unknown
- 2019-06-19 MX MX2024003178A patent/MX2024003178A/es unknown
- 2019-07-10 ZA ZA2019/04533A patent/ZA201904533B/en unknown
-
2021
- 2021-04-16 CL CL2021000950A patent/CL2021000950A1/es unknown
-
2022
- 2022-06-23 US US17/808,319 patent/US20230042095A1/en not_active Abandoned
- 2022-06-30 JP JP2022105552A patent/JP7459173B2/ja active Active
-
2024
- 2024-03-19 JP JP2024044049A patent/JP2024075682A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7036909B2 (ja) | 抗ｃｄ３８抗体および使用方法 | |
| JP6839761B2 (ja) | 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP7257364B2 (ja) | 抗ｃｄ１３７抗体 | |
| JP6839772B2 (ja) | 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP2020512388A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| JP6518005B2 (ja) | Ｐｄ−ｌ１抗体 | |
| JP7649744B2 (ja) | Ｂｔｎ３ａ結合タンパク質及びその使用 | |
| RU2017117596A (ru) | Связывающие молекулы, специфичные в отношении CD73, и пути их применения | |
| KR20170068458A (ko) | 항-ｎｋｇ2ａ 항체를 사용한 치료 요법 | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| CN104903352A (zh) | 多价结合蛋白组合物 | |
| CA2957491A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| JP2022505925A (ja) | 抗ｔｉｍ－３抗体 | |
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| EP3694879A1 (en) | Antibodies targeting pdl1 and methods of use thereof | |
| WO2022002063A1 (zh) | 一种4-1bb结合蛋白及其应用 | |
| JP2023506262A (ja) | 抗ｂｃｍａ ｃａｒ抗体、コンジュゲートおよび使用方法 | |
| AU2018214222B2 (en) | Inhibition of platelet aggregation using anti-human GPVI antibodies | |
| JP7059389B2 (ja) | 抗ｐｄ－１抗体との組み合わせのための抗ｃｄ１３７抗体 | |
| US20250313631A1 (en) | Treatment and prevention of cancer using vista antigen-binding molecules | |
| JP7059388B2 (ja) | 抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体 | |
| AU2019358442B2 (en) | Antibodies targeting CD137 and methods of use thereof | |
| EP4491631A1 (en) | Anti-pd-1 antibody binding domain and immunoconjugate | |
| CN117177994A (zh) | 包含新颖pd-1结合域之多特异性结合部分 |